Vivos Therapeutics price target lowered to $6 from $8.25 at Alliance Global Partners

Alliance Global Partners analyst Scott Henry lowered the firm’s price target on Vivos Therapeutics (VVOS) to $6 from $8.25 and keeps a Buy rating on the shares after the company reported Q3 earnings with results that were at the lower end of expectations. Results will take time to improve given the business model shift from dentists to sleep specialists, notes the firm, which expects “flattish results” in Q4 and lowered its revenue forecast for 2025.